BioStock: Elicera Therapeutics' iTANK-platform reaches proof-of-concept

Elicera Therapeutics presented preclinical proof-of-concept data for its patented iTANK platform this week. The data helps make the case that iTANK, used for the optimisation of immunotherapies, enables CAR T-cell therapies to overcome two of the major challenges in treating solid tumours. Until now, conventional CAR T-cell therapies have been unable to treat solid tumours.

Read the article at biostock.se:

https://www.biostock.se/en/2021/10/elicera-therapeutics-itank-platform-reaches-proof-of-concept/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se